Title: ANTIBODY AGAINST FIBROBLAST GROWTH FACTOR-23 Inventors: Yuji YAMAZAKI, et al. Appl. No.: 10/500,296 Dkt. No. 081356-0218 SABE/YT/vlw/bhc (7/12/06)

Amendment (10 pgs.);

Amendment Transmittal with Petition for Extension of Time (2 pgs.);

Exhibit A – pages 58-62 of the <u>Encyclopedia of Molecular Biology</u> (7 pgs.); Certified Translation of Japanese Patent Application No. 262020/2002 (156 pgs.);

Certified Translation of Japanese Patent Application No. 401689/2001 (128 pgs.);

Credit Card Payment Form for \$1,620.00 (1 pg.).

Due Date: July 13, 2006 Date Filed: July 12, 2006 Transaction Code: PUZJAA PTO Log No.: /5//0

PTO Log No.:

Attorney Initials: SABE Insp. By:

Approved for U.S. Patent and Trademark Of

MODIFIED PTO/SB/08 (08-00) through 10/31/2002. OMB 0651-0031 U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.						DTCA DATA DOTIOTO O O IVIN		
		Substitute for form 1	449B/	PTO	Complete if Known CT/PTO 2 8 JUN 208			
INFORMATION DISCLOSURE					Application Number	Unassigned		
STATEMENT BY APPLICANT				CANT	Filing Date	Concurrently Herewith		
Date Submitted: June 28, 2004 (use as many sheets as necessary)					First Named Inventor	Yuji YAMAZAKI		
					Group Art Unit	Not yet assigned		
					Examiner Name	Not yet assigned		
Sheet		1	of	1	Attorney Docket Number	081356-0218		

U.S. PATENT DOCUMENTS								
	Cite No.	U.S. Patent Document		N	Date of Publication of	Pages, Columns, Lines, Where Relevant		
Examiner Initials*		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Office <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>			
<b>3</b> (c)	A1	WO 02/076467	Genzyme Corporation	3/22/2002					
1	A2	WO 01/66595	Chiron Corporation & Kyoto University	3/7/2001					
112	A3	WO 01/66596	Chiron Corporation & Kyoto University	3/7/2001					
						T			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	™
16	A4	International Search Report	
	A5 _	Takashi SHIMADA et al., "Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia", Proc. Natl. Acad. Sci., USA, 5/22/2001, Vol. 98, Issue 11, pp. 6500-6505.	- *
	A6 .	Yuji YAMAZAKI et al., "Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia", The Journal of Clinical Endocrinology & Metabolism, (11/2002), Vol. 87, No. 11, pp. 4957-4966.	
	A7	Yuji YAMAZAKI et al, "Detection of Circulating FGF-23 by Monoclonal Antibodies Against Recombinant Human FGF-23", Journal of the American Society of Nephrology, (9/2002), Vol. 13, (Program and Abstract Issue), pg. 499A.	
	8A	Takashi SHIMADA et al, "FGF-23 Is a Novel Humoral Factor Regulating Vitamin D Metabolism", Journal of the American Society of Nephrology, (9/2002), Vol. 13, (Program & Abstract Issue), pg. 28A.	
	A9	Takashi SHIMADA et al., "Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo", Endocrinology, (8/2002), Vol. 143, No. 8 pp. 3179-3182.	
	A10	"Yuji YAMAZAKI et al, "Development of the ELISA System Using Monoclonal Antibodies against FGF-23 and Demonstration of Increased Plasma Concentration of FGF-23 in Tumor-Induced Osteomalacia", ENDO, 2002, The Endocrine Society's 84 <sup>th</sup> Annual Meeting, Program & Abstract, pg. 66.	
R	A11	-Y. YAMAZAKI et al., "FGF-23 Protein is Present in Normal Plasma and Is Increased in Patients with Tumor- Induced Osteomalacia", (9/2002), The Journal of Bone and Mineral Research, Vol. 17, suppl. 1, pg. 159.	

Examiner Signature Considered Considered	1/3/06

\*EXAMINER: In that if reference considered, whether or not cliation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sant to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number, <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.